Table 3. . Results of liver transplantation for neuroendocrine tumors liver metastases (series of at least 10 patients, published in English after 1990).
| Study | Postoperative mortality | Overall survival | Disease-free survival | Survival prognostic factors | Ref. |
|---|---|---|---|---|---|
| Multicentric series | |||||
| Le Treut | 14%, risk factors:
|
5 years: 47% | 5 years: 20% | UAE, DP primary, HMG. DP primary + HMG = 12% 5 year OS | [11] |
| Le Treut | 10%, risk factors:
|
5 years: 52% | 5 years: 30% | Major concomitant surgery, poorly differentiated tumor, HMG. After 2000: HMG, age >45, concomitant resection | [9] |
| Bechstein | 10% | 3 years: 52% | – | – | [4] |
| N'Guyen | – | 5 years: 49% | – | Low serum albumin level in recipient | [7] |
| Gedaly | 5 years: 48% | 5 years: 32% | Better survival if wait time >67 days | [12] | |
| Monocentric series | |||||
| Coppa | – | 5 years: 67% after LR, 70% after LT (p = NS) | 5 years: 29% after LR, 53% after LT (p = NS) | – | [5] |
| Van Vilsteren | 5% (n = 1) | 1 year: 87% | 1 year: 77% | Ki67 correlated with survival, but not with recurrence | [13] |
| Rosenau | 5% (n = 1) | 5 years: 80% | 5 years: 21% | % of Ki67-positive cells and aberrant staining pattern for E-cadherin– hepatichilar or regional lymph node at LT | [8] |
| Marin | 10% (n = 1) | 3 years: 57% | – | – | [14] |
| Cahlin | 0% | 2 years: 10% in carcinoid tumors 2 years: 67% in pancreatic NETs | 2 years: 75% in carcinsoid tumors 2 years: 33% in pancreatic NETs | – | [15] |
| Florman | 27% | 5 years: 36% | – | – | [16] |
| Lang | 8% (n = 1) | 5 years: 77% | – | – | [17] |
| Lang | 0 | 5 years: 40% | 5 years: 10% | – | [18] |
| Routley | 0 | 5 years: 57% | – | – | [19] |
| Ahlman | 0% | – | – | – | [20] |
| Personal series | 12% | 5 years: 55% | 5 years: 45% | – | |
DP: Duodenopancreas; HMG: Hepatomegaly; LR: Liver resection; LT: Liver transplantation; NET: Neuroendocrine tumor; NS: Not significant; OS: Overall survival; UAE: Upper abdominal exenteration.